Nanobiotix Closes $71 Million Funding Round for Oncology Pipeline

Nanobiotix, a leading late clinical-stage nanotherapeutics company, has announced it has secured $71,000,000 in funding from investors. Incorporated in 2003, the company is dedicated to pioneering new approaches to significantly improve patient outcomes for millions around the world by building new therapies atom by atom. This substantial capital infusion marks a pivotal moment, poised to accelerate the development and potential commercialization of its innovative treatment platforms. The core of Nanobiotix's global development strategy is focused on NBTXR3 (JNJ-1900), the first product candidate from its nanoradioenhancer platform. This technology aims to increase the tumor-killing effect of radiotherapy without increasing damage to surrounding healthy tissues and to synergize with other anti-cancer therapies, such as immune checkpoint inhibitors. Complementing NBTXR3, the Curadigm Nanoprimer Platform represents the company’s second technology platform. Curadigm's innovative approach seeks to improve treatment outcomes across several therapeutic classes by optimizing drug bioavailability and efficacy through systemic delivery enhancement. Nanobiotix plans to strategically deploy the newly raised capital to advance its ongoing clinical development programs, particularly for NBTXR3, and to further mature the Curadigm Nanoprimer Platform. The funding will also be directed towards strengthening the company's operational capabilities, expanding research and development efforts, and supporting broader strategic growth initiatives. This investment underscores investor confidence in Nanobiotix's physical-based approaches to address high unmet medical needs. The company, dual-listed on Euronext in Paris and the Nasdaq Global Select Market, aims to solidify its position as a leader in nanotherapeutics, bringing highly effective and generalized solutions to patients globally.